Apogee director cashes out 34,824 shares in merger
Rhea-AI Filing Summary
Apogee Therapeutics, Inc. (APGE) director William A. Jones Jr. reported the disposition of company equity in connection with a merger under an Agreement and Plan of Merger among Andor LLC, Andor Merger Co., Apogee Therapeutics, Inc. and AbbVie Inc. on September 3, 2026.
Jones disposed of 34,824 shares of common stock and three blocks of vested stock options covering 10,370, 14,461 and 7,657 shares. Each option was cashed out for the cash value of the per share merger consideration of $135.11 minus its exercise price, and Jones reported holding no shares of common stock directly after the transactions. No Rule 10b5-1 plan is reported.
Positive
- None.
Negative
- None.
Insider Trade Summary
Disposition: 67,312 shares
Disposition
4 txns
Insider
JONES WILLIAM A JR
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to Buy) F3, F2 | 10,370 | -- | -- |
| Disposition | Stock Option (Right to Buy) F3, F2 | 14,461 | -- | -- |
| Disposition | Stock Option (Right to Buy) F3, F2 | 7,657 | -- | -- |
| Disposition | Common Stock F1 | 34,824 | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 0 contracts (Direct);
Common Stock — 0 shares (Direct)
Footnotes (3)
- F1. The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the "Merger Agreement"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc.
- F2. The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
- F3. Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option.
Key Figures
Common stock shares disposed: 34,824 shares
Stock option shares disposed (grant 1): 10,370 option shares
Exercise price (grant 1): $43.85 per share
+5 more
8 metrics
Common stock shares disposed
34,824 shares
Shares of Apogee Therapeutics common stock disposed of on September 3, 2026 under the merger agreement
Stock option shares disposed (grant 1)
10,370 option shares
Vested stock options with a June 5, 2034 expiration, disposed of on September 3, 2026
Exercise price (grant 1)
$43.85 per share
Exercise price of the disposed vested stock options expiring June 5, 2034
Stock option shares disposed (grant 2)
14,461 option shares
Vested stock options with a June 17, 2035 expiration, disposed of on September 3, 2026
Exercise price (grant 2)
$41.66 per share
Exercise price of the disposed vested stock options expiring June 17, 2035
Stock option shares disposed (grant 3)
7,657 option shares
Vested stock options with a June 9, 2036 expiration, disposed of on September 3, 2026
Exercise price (grant 3)
$85.00 per share
Exercise price of the disposed vested stock options expiring June 9, 2036
Per share merger consideration
$135.11 per share
Cash merger consideration used to calculate payments for disposed stock options under the merger agreement
Key Terms
Agreement and Plan of Merger, per share merger consideration, exercise price
3 terms
Agreement and Plan of Merger regulatory
"pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026"
An Agreement and Plan of Merger is a formal document where two companies agree to combine into one, outlining how the process will happen. It’s like a step-by-step plan for merging, and it matters because it shows both sides have agreed on the details before the official transition takes place.
exercise price financial
"of $135.11 over the exercise price of such option"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
What did APGE director William A. Jones Jr. report on this Form 4?
He reported disposing of 34,824 shares of Apogee Therapeutics common stock and three vested stock option grants covering 10,370, 14,461 and 7,657 shares, all in connection with a merger involving AbbVie Inc., with the equity exchanged for cash consideration.
Were the APGE insider’s transactions under a Rule 10b5-1 trading plan?
No. The filing indicates that the Rule 10b5-1 checkbox is not marked, and there is no footnote stating that the transactions were made under a Rule 10b5-1 or other pre-arranged trading plan.
What are the exercise prices of the disposed APGE stock options?
The disposed stock options reported by the Apogee Therapeutics director had exercise prices of $43.85, $41.66 and $85.00 per share, with expiration dates in June 2034, June 2035 and June 2036, respectively.
AI-generated analysis. How Rhea-AI works. Not financial advice.
